Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
May 10, 2016 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, May 10, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Announces Publication on Biomarkers to Quantify Utrophin Protein and Regeneration of Muscle Fibres in DMD
March 15, 2016 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, March 15, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD
January 21, 2016 07:00 ET
|
Summit Therapeutics plc
OXFORD, UK, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’)...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy
September 08, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Netherlands - September 8,
2014 - Prosensa Holding N.V. (NASDAQ: RNA), the
biopharmaceutical company focusing on RNA-modulating...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Awarded $200,000 Research Grant from PPMD
June 27, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, June 27, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Completes Enrollment in Natural History Study of Duchenne Muscular Dystrophy
June 25, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, June 25, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Holding N.V. to Webcast Conference Call Discussing 1st Quarter 2014 Financial Results and Corporate Update on May 20, 2014
May 13, 2014 08:57 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, May 13, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that the
Company will host a conference call and live audio webcast on
Tuesday, May 20,...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa to Present at the 66th Annual American Academy of Neurology (AAN) Annual Meeting and the 39th Annual Deutsche Bank Health Care Conference
April 28, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, April 28, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical
company focusing on rare diseases with a high unmet medical need,
today...
![CureDuchenne logo](/news-release/logo/220973/0/220973.jpg?lastModified=12%2F10%2F2016%2018%3A09%3A32&size=2)
CureDuchenne Announces Third Annual Scientific Summit and Worlwide Webcast
January 24, 2012 13:51 ET
|
CureDuchenne
NEWPORT BEACH, Calif., Jan. 24, 2012 (GLOBE NEWSWIRE) -- CureDuchenne, a national nonprofit that funds research to find a cure for Duchenne muscular dystrophy, a lethal muscle disease that affects...